Cryo-Cell International, Inc. (CCEL)
NYSEAMERICAN: CCEL · Real-Time Price · USD
3.250
+0.280 (9.43%)
Mar 26, 2026, 4:00 PM EDT - Market closed
Cryo-Cell International Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Cryo-Cell International in the last 12 months.
Price Target: n/a
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Cryo-Cell International is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 20, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $9 → $8.5 | Strong Buy | Maintains | $9 → $8.5 | +161.54% | Mar 4, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +269.23% | Aug 29, 2022 |
Financial Forecast
Revenue This Year
30.52M
from 31.57M
Decreased by -3.31%
Revenue Next Year
n/a
from 30.52M
EPS This Year
-0.43
from -0.30
EPS Next Year
n/a
from -0.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 |
|---|---|
| High | 31.4M |
| Avg | 30.5M |
| Low | 29.3M |
Revenue Growth
| Revenue Growth | 2026 |
|---|---|
| High | -0.5% |
| Avg | -3.3% |
| Low | -7.1% |
EPS Forecast
| EPS | 2026 |
|---|---|
| High | -0.44 |
| Avg | -0.43 |
| Low | -0.41 |
EPS Growth
| EPS Growth | 2026 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.